Literature DB >> 2963169

Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients.

G M London1, M C De Vernejoul, F Fabiani, S J Marchais, A P Guerin, F Metivier, A M London, F Llach.   

Abstract

Echocardiographic assessment of left ventricular function was performed in 66, stable hemodialysis patients and 50 normal controls matched for sex, age and arterial blood pressure. On the basis of bone histology, hemodialysis patients were classified into two groups: (1) patients with normal bone resorption; and (2) patients with active secondary hyperparathyroidism characterized by an increased bone resorption. Left ventricular function of these two subgroups were compared together as well as with the echocardiographic characteristics of normal controls. In comparison with normal controls, hemodialysis patients with normal bone resorption had an increased left ventricular volume (P less than 0.001) and left ventricular mass (P less than 0.001) with a similar left ventricular mass-to-volume ratio. Their systolic arterial pressure--mass-to-volume ratio correlation was similar to that of normal controls, indicating an adequate myocardial hypertrophy. Patients with increased bone resorption had high parathormone and alkaline phosphatase levels; though the left ventricular dilation was similar to that of hemodialysis patients with normal bone resorption, the left ventricular mass was lower (P less than 0.001) and was similar to the left ventricular mass of normal controls. In addition, patients with increased bone resorption had a lower mass-to-volume ratio (P less than 0.001) and their systolic arterial pressure--mass-to-volume ratio correlation exhibited a significant downward shift (P less than 0.001), suggesting an inadequate myocardial hypertrophy. Patients with increased bone resorption and secondary hyperparathyroidism had an increased heart rate, a higher systolic arterial pressure and end-systolic stress. Furthermore, they had an increased velocity of fiber shortening (P less than 0.01) and shorter left ventricular ejection time (P less than 0.001). In summary, present data suggest the possibility that parathormone may exert myocardial effects in hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2963169     DOI: 10.1038/ki.1987.293

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

Review 1.  Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy.

Authors:  Xiaoliang Wang; Jiang Liu; Christopher A Drummond; Joseph I Shapiro
Journal:  Expert Opin Ther Targets       Date:  2017-04-03       Impact factor: 6.902

2.  Abnormal left ventricular mass and aortic distensibility in pediatric dialysis patients.

Authors:  Renee F Robinson; Milap C Nahata; Elizabeth Sparks; Curt Daniels; Donald L Batisky; John R Hayes; John D Mahan
Journal:  Pediatr Nephrol       Date:  2004-10-27       Impact factor: 3.714

3.  Secondary hyperparathyroidism and target organs in chronic kidney disease.

Authors:  M Nikodimopoulou; S Liakos
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

4.  Inappropriate left ventricular mass in children and young adults with chronic renal insufficiency.

Authors:  Francesca Raimondi; Marcello Chinali; Daniela Girfoglio; Margherita Benincasa; Luciano Pasquini; Francesco Emma; Giovanni de Simone; Maria Chiara Matteucci
Journal:  Pediatr Nephrol       Date:  2009-05-15       Impact factor: 3.714

5.  Effect of intermittent versus continuous parathyroid hormone in the cardiovascular system of rats.

Authors:  Sanela Smajilovic; Rasmus Schaal-Jensen; Reza Jabbari; Una Smajilovic; Stig Haunso; Jacob Tfelt-Hansen
Journal:  Open Cardiovasc Med J       Date:  2010-03-31

6.  Hypertension and hyperparathyroidism are associated with left ventricular hypertrophy in patients on hemodialysis.

Authors:  N Al-Hilali; N Hussain; A I Ataia; M Al-Azmi; B Al-Helal; K V Johny
Journal:  Indian J Nephrol       Date:  2009-10

7.  Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD.

Authors:  Gérard M London; Sylvain J Marchais; Alain P Guérin; Pierre Boutouyrie; Fabien Métivier; Marie-Christine de Vernejoul
Journal:  J Am Soc Nephrol       Date:  2008-05-14       Impact factor: 10.121

8.  Survival after parathyroidectomy in patients with end-stage renal disease and severe hyperparathyroidism.

Authors:  Andrea Trombetti; Catherine Stoermann; John H Robert; François R Herrmann; Pietra Pennisi; Pierre-Yves Martin; René Rizzoli
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

Review 9.  Cardiovascular complications of pediatric chronic kidney disease.

Authors:  Mark M Mitsnefes
Journal:  Pediatr Nephrol       Date:  2006-11-21       Impact factor: 3.714

10.  Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism.

Authors:  Irene Ruderman; Edward R Smith; Nigel D Toussaint; Tim D Hewitson; Stephen G Holt
Journal:  BMC Nephrol       Date:  2018-05-15       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.